Lipid Nanomaterials for LPC Solubility and Hemolysis Reduction
Solution Overview
Problem
Lysophosphatidylcholine (LPC) compounds have low solubility in aqueous phases, leading to low bioavailability and stability issues in pharmaceutical formulations, and cause hemolysis and erythrocyte aggregation, as well as local irritation upon administration.
Innovation Solution
Formulating LPC into a lipid nanomaterial using a mixture of triglycerides, oils, and lecithin, which improves solubility, reduces toxicity, and minimizes hemolysis and erythrocyte aggregation, and is administered in a pharmaceutical formulation for oral or parenteral use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If LPC is dissolved in aqueous phase for pharmaceutical formulation, then it can be administered systemically, but solubility is very low and bioavailability is reduced
Solution Approach 1:
The patent uses liposomes as intermediary carriers to solubilize LPC in aqueous environments. The liposome structure with phospholipid bilayer serves as a mediator that encapsulates hydrophobic LPC molecules, enabling their dissolution in water-based pharmaceutical formulations while maintaining stability and bioavailability.
Solution Approach 2:
The patent creates a composite pharmaceutical formulation combining LPC with liposome components (phospholipids, cholesterol). This composite structure allows the hydrophobic LPC to be incorporated into the lipophilic core of liposomes, achieving solubility in aqueous phase while preserving therapeutic efficacy.
2Ease of operation
If LPC is administered in solubilized formulations, then it can be delivered systemically, but it precipitates in body fluid and tissues immediately after administration
Solution Approach 1:
Liposomes act as protective intermediaries that prevent LPC precipitation in body fluids. The phospholipid bilayer membrane of liposomes maintains LPC in a solubilized state during circulation, releasing it gradually at the target site rather than allowing immediate precipitation in tissues.
Solution Approach 2:
The patent modifies the physical-chemical parameters of LPC by incorporating it into liposomes, changing its solubility characteristics and critical micelle concentration. This parameter change prevents precipitation in physiological conditions while maintaining the ability to deliver LPC systemically.
3Reliability
If LPC is administered therapeutically, then it activates immunocompetent cells and treats infections, but it induces hemolysis and erythrocyte aggregation
Solution Approach 1:
Liposomes serve as intermediary carriers that deliver LPC to target sites while minimizing direct contact with erythrocytes. This reduces hemolysis and erythrocyte aggregation caused by direct LPC exposure, while still allowing LPC to reach and activate immunocompetent cells at infection sites.
Solution Approach 2:
The patent enables localized delivery of LPC to sites of infection and inflammation, where it can activate immunocompetent cells. The liposome formulation allows LPC to concentrate at target tissues while reducing systemic exposure that causes hemolysis and erythrocyte aggregation, achieving local quality control of therapeutic action.
4Ease of operation
If LPC is administered subcutaneously, then it can be delivered locally, but it causes remarkable local irritation
Solution Approach 1:
Liposomes act as intermediary carriers that reduce direct contact between LPC and local tissues during subcutaneous administration. This minimizes local irritation while still delivering LPC to the intended site, allowing safe local administration of the therapeutic agent.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lipid nanomaterial formulation enhances the solubility and reduces toxicity and hemolysis of LPC, improving its stability and bioavailability, making it suitable for therapeutic use in conditions like sepsis and bacterial infections without causing local irritation.
Implementation Method 1
a lipid nanomaterial, including: (a) a lipid construct containing a triglyceride, oil, and lecithin; and (b) lysophosphatidylcholine or an ether derivative thereof
Data Source
AI summary
The present invention relates to a lipid nanomaterial containing lysophosphatidylcholine or an ether derivative thereof, a method for preparing the same, a method for reducing erythrocyteolysis and hemagglutination using the compound, and a pharmaceutical agent containing the lipid nanomaterial. The present invention contains lysophosphatidylcholine or an ether derivative thereof as an active ingredient, and can be useful as a treatment agent for septicemia, bacterial infection diseases, and the like.